Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P26992
UPID:
CNTFR_HUMAN
Alternative names:
-
Alternative UPACC:
P26992; Q5U050
Background:
The Ciliary neurotrophic factor receptor subunit alpha (CNTFR alpha) is a crucial component in the signaling pathway for neurotrophic cytokines, specifically binding to CNTF. It forms a receptor complex with CLCF1/CLC and CRLF1/CLF-1, essential for neuronal survival and function. Additionally, it serves as a receptor for the neuroprotective peptide humanin, in conjunction with IL6ST/GP130 and IL27RA/WSX1, highlighting its significance in neuroprotection.
Therapeutic significance:
Understanding the role of Ciliary neurotrophic factor receptor subunit alpha could open doors to potential therapeutic strategies, particularly in neurodegenerative diseases and conditions requiring neuroprotection.